Tenax Therapeutics(TENX) - 2025 Q1 - Quarterly Results

Form 8-K: Current Report This report details the current financial disclosures and related exhibits filed by Tenax Therapeutics, Inc Item 2.02 Results of Operations and Financial Condition Tenax Therapeutics, Inc. announced its Q1 2025 financial results via a press release, which is not considered a formal filing under the Exchange Act - The company issued a press release on May 14, 2025, to announce its financial results for the first quarter ended March 31, 2025[4] - The press release is attached as Exhibit 99.1 and incorporated by reference[4] - The information in this item, including the exhibit, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to its liabilities, unless specifically referenced in a formal filing[5] Item 9.01 Financial Statements and Exhibits This section details the exhibits filed with the Form 8-K, primarily the press release containing financial results Exhibit List | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press release dated May 14, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures The report was officially signed and authorized by Christopher T. Giordano, President and CEO of Tenax Therapeutics, Inc. on May 14, 2025 - The report was signed on behalf of the registrant on May 14, 2025[9] - The signatory was Christopher T. Giordano, President and Chief Executive Officer[9]